The abstract frames PELNVs as promising but nascent, and does not present clinical efficacy or standardized delivery performance for CNS disorders.
Simplified
As global population aging intensifies, the incidence of central nervous system (CNS) disorders escalates, while obstacles like the (BBB) impede effective medication delivery. (PELNVs), as innovative therapeutic carrier, have garnered significant interest in their capacity to transport medications across the BBB. A substantial emphasis is focused on the diverse therapeutic potential of PELNVs, underscoring their direct neuroprotective, anti-inflammatory, and antioxidant properties, along with their nascent function in altering the to indirectly mitigate neuroinflammation. We subsequently compile information elucidating the processes by which PELNVs transport therapeutic cargo to the brain, including receptor-mediated transcytosis and their tailored targeting techniques. Ultimately, we address the prevailing difficulties. In summary, PELNVs embody a revolutionary, multi-faceted strategy with significant promise to address the persistent challenges in CNS medication delivery and treatment.
Full Text
We can’t show the full text here under this license.
